BCL2 and colorectal cancer: The more pronounced effects of rosuvastatin on Bcl-2 suppression in Caco-2 cells, reducing expression to approximately 0.2 fold of LPS controls (Figure 9E), underscore the differential potency of these agents and suggest that rosuvastatin may be particularly effective at disabling the anti-apoptotic machinery in certain colorectal cancer subtypes.